Fibrocell Science Stock Price - FCSC

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Fibrocell Science Inc FCSC NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 3.00 0.00 0.00 0.00 3.00 20:00:00
Bid Price Ask Price Spread Spread % News
2.99 4.40 1.41 32.05% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 3.00 USD

Fibrocell Science Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 29.27M 9.76M 7.55M $ - $ - -1.51 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 37.50%

more financials information »

Fibrocell Science News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical FCSC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months2.993.012.993.00100,1070.010.33%
1 Year1.973.031.702.6688,8181.0352.28%
3 Years11.1523.17951.453.57344,892-8.15-73.09%
5 Years26.4538.001.456.89282,499-23.45-88.66%

Fibrocell Science Description

Fibrocell Science Inc is active in the healthcare sector. It is an autologous cell and gene therapy company focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue, and joints. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa and its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.